OBJECTIVE: Recent findings have evidenced the beneficial activity of myo-Inositol (myo-Ins) for the treatment of airways diseases. The study was designed to examine its efficacy in counteracting respiratory diseases complications, using nebulization as delivery route.

PATIENTS AND METHODS: 15 patients with different clinical features of airways diseases were treated for 15 days on average with nebulized myo-Ins. Peripheral capillary oxygen saturation (SpO2) levels and symptoms distribution were analyzed.

RESULTS: All the patients experienced a significant increase in the SpO2 levels after the treatment with nebulized myo-Ins [98% (IQR 95-97.5) after the treatment vs. 96% (IQR 98-98) before the treatment] (p<0.05). Moreover, 67% of patients had a total recovery and did not manifest symptoms after the end of the treatment; the remaining 33% had a regression of the symptoms (p<0.001) with a marked improvement of their general health status.

CONCLUSIONS: Nebulized myo-Ins relieved symptoms of respiratory diseases thus reducing the related complications.